Ferring Presents Phase III Data for a Controlled Release Misoprostol Vaginal Delivery System for Labour Induction at the First European Congress on Intrapartum Care

New Drug Approvals

MISOPROSTOL

READ AT

http://www.nationalpost.com/markets/news/Ferring%2BPresents%2BPhase%2BData%2BControlled%2BRelease%2BMisoprostol%2BVaginal/8429878/story.html

Misoprostol is a synthetic prostaglandin E1 (PGE1) analog that is used for the prevention of nonsteroidal anti-inflammatory drug (NSAID) induced gastric ulcers, to treat missed miscarriage, to induce labor, and as an abortifacient. The latter use is controversial in theUnited States. Misoprostol was invented and marketed by G.D. Searle & Company (nowPfizer) under the trade name Cytotec, but other brand-name and generic formulations are now available as well.

Misoprostol is approved for use in the prevention of NSAID induced gastric ulcers. It acts upon gastric parietal cells, inhibiting the secretion of gastric acid via G-protein coupled receptor mediated inhibition of adenylate cyclase, which leads to decreased intracellularcyclic AMP levels and decreased proton pump activity at the apical surface of the parietal cell. Because

View original post

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s